一周肌内或皮内暴露前预防接种人二倍体细胞疫苗或Vero细胞狂犬病疫苗,一年后模拟暴露后预防:一项评估免疫原性与安全性的III期开放标签随机对照试验
这项多中心开放标签对照试验将570名2-64岁健康参与者随机分入5组,比较一周与经典三周暴露前预防方案(含人二倍体细胞疫苗或Vero细胞狂犬病疫苗的肌内或皮内接种),一年后给予模拟暴露后预防。结果显示一周方案末次接种后14天血清阳转率为96.7%至97.2%,三周方案为100%,但一周方案相比三周方案血清阳转率的非劣效性未获证实。模拟暴露后预防后所有组均出现快速稳健的免疫应答,除一例外均达血清阳转,安全性良好。
要点
- 一周暴露前预防(第0、7天)末次接种后14天血清阳转率为96.7%至97.2%,三周方案(第0、7、21天)为100%。
- 一周方案相比三周方案在末次接种后14天血清阳转率上的非劣效性未获证实。
- 一年后模拟暴露后预防后,除一例外所有参与者均达血清阳转(滴度≥0.5 IU/mL),各组安全性相似。
核心结论
- 一周肌内或皮内暴露前预防方案使用人二倍体细胞疫苗或Vero细胞狂犬病疫苗可提供有效的免疫启动,使各年龄组在一年后对模拟暴露后预防产生快速稳健的回忆应答。
- 一周方案相比三周方案在末次暴露前预防接种后14天血清阳转率上的非劣效性未获证实。
研究设计与样本
- 多中心、开放标签、对照III期随机试验,纳入570名2-64岁健康参与者。
- 参与者随机分入5组:组1为一周暴露前预防(第0、7天)肌内接种1.0 mL人二倍体细胞疫苗;组2为经典三周方案(第0、7、21天)肌内接种1.0 mL人二倍体细胞疫苗;组3为一周方案每次皮内接种两剂0.1 mL人二倍体细胞疫苗;组4为一周方案肌内接种0.5 mL Vero细胞狂犬病疫苗;组5为一周方案皮内接种两剂0.1 mL Vero细胞狂犬病疫苗。
- 一年后给予模拟暴露后预防接种(人二倍体细胞疫苗或Vero细胞狂犬病疫苗两剂肌内或皮内,间隔三天)。
- 主要目标为组1相比组2在末次暴露前预防接种后14天血清阳转率(滴度≥0.5 IU/mL)的非劣效性。
主要发现
- 末次暴露前预防接种后14天血清阳转率:组1、3、4、5(一周方案)为96.7%至97.2%,组2(三周方案)为100%。
- 组1相比组2在末次暴露前预防接种后14天血清阳转率上的非劣效性未获证实。
- 模拟暴露后预防后所有组均显示快速稳健的免疫应答,除一名参与者外均达到血清阳转(滴度≥0.5 IU/mL)。
- 未观察到安全性问题,各组疫苗耐受性特征相似。
关键数值与推荐
- 血清阳转定义为狂犬病病毒中和抗体滴度≥0.5 IU/mL。
- 末次暴露前预防接种后14天血清阳转率:组1、3、4、5为96.7%至97.2%,组2为100%。
- 模拟暴露后预防后除一例外所有参与者达到血清阳转(滴度≥0.5 IU/mL)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 一周方案相比三周方案在末次暴露前预防接种后14天血清阳转率上的非劣效性未获证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Shorter rabies pre-exposure prophylaxis (PrEP) regimens may offer improved convenience and feasibility over classic 3-week regimens, for example in regions with poor access to vaccines or for travelers to rabies-endemic regions. In this multicenter, open-label, controlled trial, 570 healthy participants aged 2-64 years were randomized to receive: 1-week PrEP (vaccination days [D]0 and 7; Group 1) or classic 3-week PrEP regimen (D0, D7, and D21; Group 2) with one 1.0 mL intramuscular [IM] dose of human diploid cell culture rabies vaccine (HDCV) at each visit; 1-week PrEP with two 0.1 mL intradermal (ID) HDCV doses at each visit (Group 3); or 1-week PrEP with one 0.5 mL IM dose (Group 4) or two 0.1 mL ID doses (Group 5) of Vero cell rabies vaccine (PVRV) at each visit. Participants received simulated post-exposure prophylactic (PEP) vaccination (two IM or ID doses of HDCV or PVRV three days apart) one year later. Rabies virus neutralizing antibody titers and seroconversion (titers ≥ 0.5 IU/mL) rates were assessed 14 days and up to 1 year post-PrEP, and pre- and post-PEP. Safety was assessed throughout the study. Seroconversion rates were high 14 days post-last PrEP injection (ranging from 96.7 % to 97.2 % across groups 1, 3-5; 1-week PrEP) and reached 100 % in Group 2 (3-week PrEP). Non-inferiority of Group 1 versus Group 2 in terms of seroconversion rates 14 days post-last PrEP injection (primary objective) was not demonstrated. After simulated PEP, all groups showed rapid and robust immune responses, with all but one participant achieving seroconversion (titers ≥ 0.5 IU/mL). There were no safety concerns, and the tolerability profiles of the vaccines were similar across the groups. A 1-week, IM or ID PrEP regimen with HDCV or PVRV provided efficacious priming, enabling rapid robust anamnestic responses to simulated PEP 1 year later across age groups. ClinicalTrials.gov number: NCT03700242. WHO Universal Trial Number (UTN): U1111-1183-5743.
引用
- Quiambao BP, Lim JG, Bosch Castells V, et al. One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety. Vaccine. 2022. PMID: 35933278. doi:10.1016/j.vaccine.2022.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。